TOFERSEN

Tofersen Overview

Tofersen is an antisense oligonucleotide designed for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene. It serves as an advanced targeted therapy to reduce toxic protein production and support specialized neurological management of genetic ALS.

What Is Tofersen & How Does It Work?

Tofersen functions as an antisense oligonucleotide that specifically targets the messenger RNA produced by the mutated superoxide dismutase 1 gene. By binding to this specific genetic material, Tofersen prompts enzyme destruction of the targeted RNA, which significantly reduces the synthesis of toxic superoxide dismutase 1 protein in central nervous system tissues. Lowering levels of this abnormal protein helps protect motor neurons from progressive degeneration and reduces plasma neurofilament light chain, a key marker of nerve cell damage.

Is Tofersen FDA Approved?

The United States Food and Drug Administration granted accelerated approval to Tofersen for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene. Neurologists administer this targeted intrathecal agent to lower toxic protein buildup and slow neurodegeneration in specialized clinical settings.

What Is Tofersen Used For, Clinic Neurology

• Treating superoxide dismutase 1 mutation-associated amyotrophic lateral sclerosis in adult patients within Clinic Neurology.
• Reducing plasma neurofilament light chain levels to slow down active neurodegeneration.
• Targeting the underlying genetic driver of motor neuron damage in confirmed superoxide dismutase 1 genetic ALS.

Before Taking Tofersen: Contraindications & Precautions

Healthcare providers conduct detailed neurological evaluations, lumbar spine assessments, and genetic testing before starting treatment with Tofersen. Pre-treatment screening confirms the presence of the superoxide dismutase 1 gene mutation and helps prevent complications related to intrathecal administration and inflammatory spinal events.

Who Should Not Take Tofersen?

• Patients with a documented history of severe hypersensitivity to Tofersen or any components of the intrathecal solution.
• Individuals with severe localized skin infections or soft tissue infections directly over the lumbar puncture injection site.
• Patients with anatomical spinal obstructions that prevent safe intrathecal needle placement.

Tofersen, Pregnancy & Fertility

• Available clinical data regarding Tofersen administration in pregnant women are insufficient to inform a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes.
• Animal reproduction studies have not demonstrated direct developmental toxicity at clinically relevant exposure levels.
• Pregnant or nursing mothers should consult their neurologist to weigh potential clinical benefits against potential risks to the fetus or infant.

Tell Your Doctor Before Taking Tofersen

• Any personal history of spinal disease, lumbar surgery, or difficulty undergoing lumbar puncture procedures.
• Active symptoms of neurological inflammation, such as severe headache, neck stiffness, or vision changes.
• Current use of anticoagulant or antiplatelet medications that increase bleeding risks during spinal procedures.

Tofersen Dosage & Administration

Tofersen is supplied as a preservative-free single-dose vial administered directly into the cerebrospinal fluid via lumbar puncture. Treatment begins with an initial loading phase followed by regular maintenance doses administered by a trained healthcare provider.

Standard Tofersen Dosing

• The recommended dose is 100 mg per 15 mL administered intrathecally per treatment session.
• The loading schedule consists of three initial doses administered at two-week intervals on Day 1, Day 15, and Day 29.
• The maintenance schedule begins two weeks after the third loading dose, with one 100 mg intrathecal injection administered every four weeks thereafter.

How Tofersen Is Administered

• Administration is performed exclusively by a qualified healthcare professional using standard lumbar puncture techniques.
• A volume of 15 mL of cerebrospinal fluid is removed prior to injecting 100 mg of Tofersen over two to three minutes.
• Patients are observed following the procedure according to clinical protocols for lumbar puncture recovery.

Tofersen Clinical Efficacy & Research

Clinical trials demonstrate that Tofersen produces a rapid and sustained reduction in plasma neurofilament light chain levels, an established biomarker of axonal injury and neurodegeneration in amyotrophic lateral sclerosis. Established medical consensus confirms that targeted antisense oligonucleotide therapy significantly reduces cerebrospinal fluid superoxide dismutase 1 protein concentration in patients carrying the mutation. Ongoing research and observational follow-up studies continue to evaluate long-term trends in clinical function, respiratory vital capacity, and muscle strength preservation.

Tofersen Side Effects & Safety Profile

Tofersen requires clinical monitoring to recognize and manage neurological inflammatory events and common complications associated with lumbar puncture.

Tofersen Common Side Effects

• Spinal procedure-related effects, including post-lumbar puncture headache, back pain, and procedure site discomfort.
• Musculoskeletal symptoms, such as pain in extremities, muscle spasms, and joint stiffness.
• General side effects, including mild fever, fatigue, and elevated cerebrospinal fluid protein levels.

Serious Tofersen Adverse Events

• Myelitis and radiculitis, involving severe inflammation of the spinal cord or spinal nerve roots.
• Papilledema and elevated intracranial pressure, which may threaten vision if untreated.
• Aseptic meningitis, characterized by severe headache, neck stiffness, fever, and light sensitivity.

Managing Tofersen Side Effects

Rest flat following your intrathecal procedure and maintain adequate hydration to reduce the likelihood of post-lumbar puncture headache. Contact your neurology team immediately if you experience severe back pain, progressive weakness, numbness, neck stiffness, high fever, or changes in vision.

Tofersen Interactions & What to Avoid

Tofersen works locally within the central nervous system and does not undergo significant hepatic cytochrome P450 metabolism.

Tofersen Interactions

• Co-administration with anticoagulant or antiplatelet therapies increases the risk of bleeding or hematoma formation during the lumbar puncture procedure.
• Concomitant use with other intrathecal medications requires careful clinical evaluation to avoid chemical incompatibilities or procedural risks.
• Systemic medications generally do not interfere with Tofersen clearance due to its localized administration route.

Tofersen Food & Alcohol

• Food intake does not affect Tofersen because the medication is injected directly into the spinal fluid.
• Alcohol consumption should be limited to avoid dehydration and compounded central nervous system symptoms around procedure days.

Tofersen Missed Dose, Overdose & Storage

Adhering to scheduled loading and maintenance procedure dates is essential for maintaining therapeutic drug levels in the central nervous system.

Missed Dose of Tofersen

If a scheduled dose is missed, administer the missed dose as soon as possible and adjust subsequent dose timing to maintain prescribed intervals between procedures.

Tofersen Overdose & Emergency

An overdose during intrathecal administration requires immediate medical observation, supportive care, and monitoring of cerebrospinal fluid pressure and neurological status.

How to Store Tofersen

Store single-dose vials in a refrigerator between 2°C and 8°C (36°F to 46°F) in the original carton to protect from light, and do not freeze.

Tofersen Patient Management & Monitoring

Comprehensive patient care includes baseline biomarker measurement, routine neurological checks, and monitoring for inflammatory spinal events.

Tests Before Starting Tofersen

• Genetic testing to confirm a mutation in the superoxide dismutase 1 gene.
• Baseline plasma neurofilament light chain measurement and baseline cerebrospinal fluid analysis.
• Complete neurological examination and baseline ophthalmologic evaluation for papilledema.

Monitoring During Tofersen Treatment

• Routine monitoring for signs of myelitis, radiculitis, aseptic meningitis, and elevated intracranial pressure.
• Periodic measurement of plasma neurofilament light chain levels to evaluate biological response.
• Ongoing evaluation of lumbar puncture site healing and spinal procedure tolerance.

Tofersen Do’s and Don’ts

• Do report any new or worsening spinal pain, leg numbness, or weakness right away.
• Do follow all post-procedure resting instructions to help prevent headaches after your lumbar puncture.
• Do not miss your scheduled maintenance appointments, as consistent dosing maintains protein suppression.
• Do not ignore vision changes, severe headaches, or neck stiffness after a treatment session.

Frequently Asked Questions

References

• U.S. FDA – Tofersen prescribing information
• U.S. FDA Drugs@FDA – Tofersen approval history
• National Cancer Institute (NCI) – Neurology Treatment Protocols.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.